SILEXION THERAPEUTICS CORP Deferred Tax Assets, in Process Research and Development
SILEXION THERAPEUTICS CORP (SLXN) had Deferred Tax Assets, in Process Research and Development of $1.46 million as of 2025-12-31, per its S-1/A filed 2026-08-10.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2026-08-10
- 2025-12-31: Deferred Tax Assets, in Process Research and Development $1.46M.
- 2024-12-31: Deferred Tax Assets, in Process Research and Development $902.00K.
- 2023-12-31: Deferred Tax Assets, in Process Research and Development $780.00K.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2025-12-31 | $1.46M S-1/A · filed 2026-08-10 |
| 2024-12-31 | $902.00K S-1/A · filed 2026-08-10 |
| 2023-12-31 | $780.00K 8-K · filed 2025-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |